<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;div class="table-responsive"&gt;&lt;table class="table table-bordered align-top" border="1" summary="Meeting data"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Center&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Date&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Time&lt;/th&gt;&lt;th bgcolor="#cccccc" scope="col"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;CBER&lt;/td&gt;&lt;td&gt;September 15, 2015&lt;/td&gt;&lt;td&gt;September 15, 2015 from 8:30 a.m. to 2:30 p.m.&lt;/td&gt;&lt;td&gt;FDA White Oak Campus,&lt;br /&gt;10903 New Hampshire Avenue.,&lt;br /&gt;Building 31, The Great Room, room 1503,&lt;br /&gt;Silver Spring, MD 20993-0002&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;br /&gt;The committee will meet in open session to discuss and make recommendations on the safety and immunogenicity of Seasonal Trivalent Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59 (FLUAD) manufactured by Novartis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;br /&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;Materials for this meeting will be available on the &lt;a target="" href="[!--$wcmUrl('link','UCM427602')--]"&gt;2015 Vaccines and Related Biological Products Advisory Committee meeting main page&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;br /&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul type="disc"&gt;&lt;li&gt;Written submissions may be made to the contact person on or before September 8, 2015&lt;/li&gt;&lt;li&gt;Oral presentations on September 15, 2015 from the public will be scheduled between approximately 12:15 p.m. and 1:15 p.m.&lt;/li&gt;&lt;li&gt;Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 31, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 1, 2015.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;For those unable to attend in person, the meeting will also be Web cast. The Web cast will be available at the following link: &lt;a target="_blank" href="https://collaboration.fda.gov/cbervrbpac0915/"&gt;https://collaboration.fda.gov/cbervrbpac0915/&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Sujata Vijh or Denise Royster&lt;br /&gt;10903 New Hampshire Ave.,&lt;br /&gt;Bldg. 71, rm. 6128,&lt;br /&gt;Silver Spring, MD 20993-0002,&lt;br /&gt;240-402-7107&lt;br /&gt;e-mail: &lt;a href="mailto:Sujata.Vijh@fda.hhs.gov"&gt;Sujata.Vijh@fda.hhs.gov&lt;/a&gt; or email: Denise.Royster@fda.hhs.gov&lt;/li&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138 (301-443-0572 in the Washington, DC, area). Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. Seating for this meeting may be limited, so the public is encouraged to watch the free webcast if you are unable to attend. The link for the webcast will be available at 8 a.m. September 15, 2015 at the link above. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Sujata Vijh or Denise Royster at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). &lt;a target="_blank" href="[!--$ssExternalLink('UCM455598')--]"&gt;Official FR Notice&lt;/a&gt;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
